Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


News Briefs: Device Tax Repeal Momentum; J&J Settles Hip Suit; Mobile Medical Apps Bill

This article was originally published in The Gray Sheet

Executive Summary

Device tax repeal momentum. Johnson & Johnson/DePuy has settled a lawsuit from a California plaintiff related to injuries from the ASR hip implant. Rep. Marsha Blackburn is working on legislation to clarify FDA’s authority over mobile health apps. Zimmer will market Frontier’s Lateral Locking Cage. More news.

You may also be interested in...

Device Tax Delay Doesn’t Make The Cut, But Issue Could Be Exhumed In Budget Conference

Despite being a factor in lawmaker discussions throughout the shutdown, provisions to delay or repeal the device tax did not survive in the final agreement to reopen the federal government and raise the debt ceiling. But the issue appeared to gain more momentum than ever that companies hope can be maintained into upcoming budget conference talks.

Device Tax Repeal Gains High Profile During Shutdown, But Significant Barriers Remain

Some House Democrats and Republicans are circulating a device tax repeal proposal, including an idea for replacing the revenue, to resolve the shutdown. But the president and Democratic leaders in the Senate insist that they will only accept a clean funding bill with no Obamacare strings attached.

FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance

In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA has waited.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts